Advertisement

Topics

PubMed Journals Articles About "National Osteoporosis Foundation" RSS

17:03 EDT 24th September 2018 | BioPortfolio

National Osteoporosis Foundation PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest National Osteoporosis Foundation articles that have been published worldwide.

More Information about "National Osteoporosis Foundation" on BioPortfolio

We have published hundreds of National Osteoporosis Foundation news stories on BioPortfolio along with dozens of National Osteoporosis Foundation Clinical Trials and PubMed Articles about National Osteoporosis Foundation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of National Osteoporosis Foundation Companies in our database. You can also find out about relevant National Osteoporosis Foundation Drugs and Medications on this site too.

Showing "National Osteoporosis Foundation" PubMed Articles 1–25 of 5,200+

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Committee of National Societies Abstracts.


Association between gout and osteoporosis risk in the United Kingdom.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.


Gout as a risk factor for osteoporosis: response to comments by Kostev.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Author Index.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Poster Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Plenary Lectures Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Educational Lecture Abstract.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Satellite Symposia Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Oral Communication Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Meet-the-Expert Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Non-Sponsored Symposia Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): ESCEO Symposia Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): IOF-ESCEO Symposium Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): ESCEO-WHO Symposia Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): EUGMS-ESCEO-IOF Symposium Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): ESPRM-ESCEO-IOF Symposium Abstracts.

Comments on Feskanich et al.: Milk and other dairy foods and risk of hip fracture in men and women.

Comments on Minisola et al.: Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens.

Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens: response to comments by Chen et al.

The burden of musculoskeletal disorders in Mexico at national and state level, 1990-2016: estimates from the global burden of disease study 2016.

Worldwide, musculoskeletal (MSK) disorders are the second cause of living with disability. According to our data, in Mexico, MSK conditions are an important cause of disability, at national and state level. Preventive actions promoted by health systems to reduce the burden of MSK disorders are essential.

Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.

The antiresorptive potency varies between different bisphosphonates. We investigated the effect of stopping oral bisphosphonate treatment for postmenopausal osteoporosis (ibandronate, alendronate, risedronate) on BTMs and BMD. After stopping treatment, all three groups showed an increase in BTMs and a decrease in hip BMD; however, none returned to pre-treatment baseline values.

Multiple vertebral fractures associated with glucocorticoid-induced osteoporosis treated with teriparatide followed by kyphosis correction fusion: a case report.

Surgical treatment of multiple vertebral fractures in patients with glucocorticoid-induced osteoporosis is difficult because of a high rate of secondary fracture postoperatively. A case is described in which initial treatment with teriparatide to improve osteoporosis followed by treatment of kyphosis with correction fusion achieved a favorable outcome.

Genome-wide identification of mA-associated SNPs as potential functional variants for bone mineral density.

This study investigated the effect of the N-methyladenosine (mA)-associated SNPs on bone mineral density (BMD) and found plenty of mA-SNPs that were associated with BMD. This study increases our understanding on the regulation patterns of SNP and may provide new clues for further detection of functional mechanism underlying the associations between SNPs and osteoporosis.

Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.

A poorer functional status at the time of fracture is a predictor of non-adherence to oral bisphosphonates initiated after a hip fracture, and suggests further opportunities for optimization of secondary fracture prevention in this high-risk population.


Advertisement
Quick Search
Advertisement
Advertisement